Maze Therapeutics, Inc. Common Stock (MAZE) Stock Price
MAZEStock
$30.42+119.42%52W
Market Cap$1.69B
P/E77.66x
PEG Ratio—
Div yield—
Beta1.11
MAZE Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-45.59%
Price vs S&P 500 (4W)3.12%
VGM Score68.58
P/E Ratio (Annual)77.66x
MAZE Earnings Surprise History
Q2 25-0.77est. -1.16
Q3 25-0.66est. -0.69
Q4 25-0.65est. -0.69
Q2 26-0.76est. -0.70
MAZE Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.33
4.33
4.33
4.33
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MAZEMaze Therapeutics, Inc. Common Stock | — | — | B | $30.42 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for chronic kidney disease, cardiovascular disease, and obesity using its proprietary Compass platform. The platform identifies disease-causing genetic variants and links them to underlying biological pathways, enabling targeted therapeutic development. The company is advancing two lead programs—MZE829 and MZE782—both designed to treat chronic kidney disease.